KORU Medical Systems Presents Data Demonstrating Nursing Preference For Use Of KORU FreedomEdge Infusion System Over Manual Syringe Administration For Subcutaneous Oncology Infusion At Partnership Opportunities In Drug Delivery Conference
KORU Medical Systems Presents Data Demonstrating Nursing Preference For Use Of KORU FreedomEdge Infusion System Over Manual Syringe Administration For Subcutaneous Oncology Infusion At Partnership Opportunities In Drug Delivery Conference
KORU Medical Systems, Inc. (NASDAQ:KRMD) ("KORU Medical" or the "Company"), a leading medical technology company focused on development, manufacturing, and commercialization of innovative and patient-centric large-volume subcutaneous infusion solutions, this week presented data demonstrating nursing preference for the use of the KORU FreedomEdge Infusion System to administer subcutaneous oncology infusions in the clinic setting. The results of the case study were presented at the PODD 2024 Conference on October 28, 2024, in Boston, Massachusetts.
koru medical systems是一家領先的醫療科技公司，專注於開發、製造和商業化創新且以患者爲中心的大容量皮下輸液解決方案。本週，在波士頓馬薩諸塞州舉辦的2024年PODD會議上，該公司介紹了數據，證明護理人員更傾向於在診所環境中使用KORU FreedomEdge輸液系統進行皮下腫瘤治療的輸液。該案例研究結果表明，診所中護理人員更偏向於使用KORU FreedomEdge輸液系統來進行皮下腫瘤治療的輸液。
The objective of the Nursing Preference Study was to assess time spent with patients, impact on nursing and patient comfort, and overall nurse preference when comparing manual syringe administration versus mechanical pump administration with the KORU FreedomEdge Infusion System during subcutaneous oncology biologic drug infusions. The study was conducted by KORU Medical across 6 hospitals in Denmark with 33 nurses administering more than 3,000 infusions of a >10mL oncology drug with an average administration time of approximately 10 minutes.
護理優先研究的目標是評估與患者交流的時間，對護理人員和患者舒適度的影響，以及在比較手動注射器與KORU FreedomEdge輸液系統進行皮下腫瘤生物藥物輸液時的整體護理人員偏好。該研究由KORU Medical在丹麥的6家醫院開展，33名護士共進行了3000多次大於10毫升的腫瘤藥物輸液，平均輸注時間約爲10分鐘。
- Increased Patient Interaction: 97% of nurses reported having more time to interact with patients while using the KORU FreedomEdge Infusion System versus manual syringe administration
- Reduced Nurse Discomfort: 81% of nurses experienced less hand pain while using the KORU FreedomEdge Infusion System compared to manual syringe administration
- Ease of Use: 91% of nurses found the KORU FreedomEdge Infusion System easier to use, with a shorter setup time compared to manual syringe administration
- Reduced Patient Discomfort: 73% of nurses observed less patient pain during infusions with the KORU FreedomEdge Infusion System versus manual syringe administration
- Recommended by Nurses: 97% of nurses would recommend the KORU FreedomEdge Infusion System over manual syringeadministration, citing ease of use and reduced discomfort as key reasons
- 患者互動增加：97%的護士報告在使用KORU FreedomEdge輸液系統時有更多時間與患者交流，而不是手動注射器。
- 減少護士不適：81%的護士在使用KORU FreedomEdge輸液系統時經歷較少的手部疼痛，而與手動注射器相比。
- 易於使用：91%的護士發現KORU FreedomEdge輸液系統更易於使用，設置時間較手動注射器更短。
- 減少患者不適：73%的護士觀察到在使用KORU FreedomEdge輸液系統與手動注射器相比，輸液過程中患者的疼痛減少。
- 護士推薦：97%的護士表示他們會推薦KORU FreedomEdge輸液系統而不是手動注射器，原因是易於使用和減少不適。
Subcutaneous formulation of formerly intravenous biologics is a growing trend with oncology pharmaceutical manufacturers. There are five greater-than-5mL biologic oncology drugs that have been cleared for in-clinic administration by healthcare professionals for an estimated one million global infusions.1,2 Evidence indicates that subcutaneous administration of oncology therapy simplifies treatment protocol, reduces pressure on hospitals, and improves patients' quality of life.3 As further development of subcutaneous drug therapies increases, the optimization of drug administration has created a significant opportunity for drug delivery solutions like the KORU FreedomEdge Infusion System.
曾經爲靜脈注射的生物製藥製品轉爲皮下注射是腫瘤製藥製造商的一個增長趨勢。全球有5種大於5毫升的生物製藥腫瘤藥物已獲醫療專業人員批准在診所進行約一百萬次輸液。證據表明，腫瘤治療的皮下注射簡化了治療方案，減輕了醫院的壓力，並提高了患者的生活質量。隨着皮下藥物療法的進一步發展，藥物管理的優化爲KORU FreedomEdge輸液系統等藥物輸送解決方案創造了重要機遇。
譯文內容由第三人軟體翻譯。
